A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

计划入组 17 人 · 首次发布于 2025 年 2 月 28 日

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

计划入组 17 人 · 首次发布于 2023 年 6 月 15 日

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

计划入组 6 人 · 首次发布于 2024 年 6 月 12 日

DB-0014

HY-0014

KBhu-0014

PYC Therapeutics' VP-001 Demonstrates Sustained Vision Improvement in RP11 Patients Following Repeat Dosing

VP-315 Demonstrates Tumor Reduction in Basal Cell Carcinoma Phase 2 Trial

Immunocore Restructures R&D Leadership as Executive VP Berman Departs